Article: Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleSafety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation
AuthorsLo, CM1
Fan, ST1
Liu, CL1
Yong, BH1
Wong, Y1
Ng, IOL1
Wong, J1
Issue Date2003
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
CitationLiver Transplantation, 2003, v. 9 n. 8, p. 827-832 [How to Cite?]
DOI: http://dx.doi.org/10.1053/jlts.2003.50115
AbstractWe studied the safety of right-lobe donor hepatectomy in living donors with a positive serological test result for antibody against hepatitis B core antigen (anti-HBc). Of 54 right-lobe living liver donors, serum anti-HBc was positive in 29 donors (54%) and negative in 25 donors (46%). None had a history of hepatitis and all had normal liver biochemistry test results before surgery. Surgical data, postoperative liver function, and outcome of donors were compared according to anti-HBc status. Donors positive for anti-HBc were significantly older (median age, 42 v 31 years; P < .001), but there was no difference in other demographics and liver size. Median blood loss was greater in anti-HBc-positive donors (600 v 350 mL; P = .007). Histological examination showed no difference in degree of portal fibrosis or fatty change in liver grafts. There was no significant difference in postoperative serum transaminase levels or prothrombin times; however, anti-HBc-positive donors had greater serum bilirubin levels day 6 (26 v 21 μmol/L; P = .01) and day 7 (22 v 15 μmol/L; P = .004) after surgery. Postoperative complications developed in 10 anti-HBc-positive and 6 anti-HBc-negative donors (P = .4). All donors who developed cholestasis were positive for anti-HBc, aged 45 years or older, and had mild fatty changes of the liver. Hospital stays were similar. All donors had completely normal liver function at a median follow-up of 31 months (range, 21 to 76 months). A positive serological test result for anti-HBc should not be regarded as a contraindication for right-lobe liver donation.
ISSN1527-6465
2011 Impact Factor: 3.386
2011 SCImago Journal Rankings: 0.305
DOIhttp://dx.doi.org/10.1053/jlts.2003.50115
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorLo, CM
dc.contributor.authorFan, ST
dc.contributor.authorLiu, CL
dc.contributor.authorYong, BH
dc.contributor.authorWong, Y
dc.contributor.authorNg, IOL
dc.contributor.authorWong, J
dc.date.accessioned2010-09-06T09:41:43Z
dc.date.available2010-09-06T09:41:43Z
dc.date.issued2003
dc.description.abstractWe studied the safety of right-lobe donor hepatectomy in living donors with a positive serological test result for antibody against hepatitis B core antigen (anti-HBc). Of 54 right-lobe living liver donors, serum anti-HBc was positive in 29 donors (54%) and negative in 25 donors (46%). None had a history of hepatitis and all had normal liver biochemistry test results before surgery. Surgical data, postoperative liver function, and outcome of donors were compared according to anti-HBc status. Donors positive for anti-HBc were significantly older (median age, 42 v 31 years; P < .001), but there was no difference in other demographics and liver size. Median blood loss was greater in anti-HBc-positive donors (600 v 350 mL; P = .007). Histological examination showed no difference in degree of portal fibrosis or fatty change in liver grafts. There was no significant difference in postoperative serum transaminase levels or prothrombin times; however, anti-HBc-positive donors had greater serum bilirubin levels day 6 (26 v 21 μmol/L; P = .01) and day 7 (22 v 15 μmol/L; P = .004) after surgery. Postoperative complications developed in 10 anti-HBc-positive and 6 anti-HBc-negative donors (P = .4). All donors who developed cholestasis were positive for anti-HBc, aged 45 years or older, and had mild fatty changes of the liver. Hospital stays were similar. All donors had completely normal liver function at a median follow-up of 31 months (range, 21 to 76 months). A positive serological test result for anti-HBc should not be regarded as a contraindication for right-lobe liver donation.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationLiver Transplantation, 2003, v. 9 n. 8, p. 827-832 [How to Cite?]
DOI: http://dx.doi.org/10.1053/jlts.2003.50115
dc.identifier.doihttp://dx.doi.org/10.1053/jlts.2003.50115
dc.identifier.epage832
dc.identifier.hkuros85317
dc.identifier.isiWOS:000184454600007
dc.identifier.issn1527-6465
2011 Impact Factor: 3.386
2011 SCImago Journal Rankings: 0.305
dc.identifier.issue8
dc.identifier.openurl
dc.identifier.pmid12884195
dc.identifier.scopuseid_2-s2.0-0041989678
dc.identifier.spage827
dc.identifier.urihttp://hdl.handle.net/10722/88312
dc.identifier.volume9
dc.languageeng
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021
dc.publisher.placeUnited States
dc.relation.ispartofLiver Transplantation
dc.relation.referencesReferences in Scopus
dc.rightsLiver Transplantation. Copyright © John Wiley & Sons, Inc.
dc.subject.meshAdult
dc.subject.meshBilirubin - blood
dc.subject.meshFemale
dc.subject.meshHepatitis B Antibodies
dc.subject.meshHumans
dc.subject.meshLiver Transplantation - immunology - methods
dc.subject.meshLiving Donors
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPostoperative Complications
dc.subject.meshTreatment Outcome
dc.titleSafety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong